PHENETH-LAD
 | |
| Clinical data | |
|---|---|
| Other names | PHENETHLAD; PHENETHY-LAD; PHENETHYLAD; 6-(β-Phenethyl)-6-nor-LSD; N-Phenethyl-nor-LSD; N,N-Diethyl-6-phenethyl-6-norlysergamide; N,N-Diethyl-6-(2-phenylethyl)-9,10-didehydroergoline-8β-carboxamide |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C27H31N3O |
| Molar mass | 413.565 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
PHENETH-LAD, or PHENETHY-LAD, also known as 6-(β-phenethyl)-6-nor-LSD, is a drug of the lysergamide family related to lysergic acid diethylamide (LSD).[1][2][3][4][5] It is the derivative of LSD in which the methyl group at the 6 position has been replaced with a phenylethyl moiety.[1][2][3]
The drug failed to substitute for LSD in rodent drug discrimination tests, with a maximum of 25 or 50% LSD-appropriate responding at the highest assessed dose.[1][4][5] Unlike other 6-substituted lysergamides, PHENETH-LAD was not assessed at the serotonin receptors.[1][5] According to Alexander Shulgin in his book TiHKAL (Tryptamines I Have Known and Loved), PHENETH-LAD produced no effects in humans at a dose of 500 μg.[3] He has specified the potentially active dose as being >350 μg and its hallucinogenic potency being less than 30% of that of LSD.[2][6]
PHENETH-LAD was first described in the scientific literature by Andrew Joseph Hoffman of the lab of David E. Nichols at Purdue University in 1985.[4] Its effects in humans were first described by Shulgin by 1994.[6][3]
See also
[edit]References
[edit]- ^ a b c d Pfaff RC, Huang X, Marona-Lewicka D, Oberlender R, Nichols DE (1994). "Lysergamides revisited". NIDA Research Monograph. 146: 52–73. PMID 8742794.
- ^ a b c Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN 978-0-12-433951-4.
- ^ a b c d Shulgin A, Shulgin A (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252. "With success in the preparation of the rather stable nor-LSD intermediate, any number of 6-substituted nor-LSD homologues and analogues can be synthesized. [...] Several analogues are in the chemical literature, and some of them have been explored in direct comparison to LSD. Here are a few examples: [...] N-Phenethyl-nor-LSD (PHENETH-LAD). Nothing at 500 μg."
- ^ a b c Hoffman AJ, Nichols DE (September 1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry. 28 (9): 1252–1255. doi:10.1021/jm00147a022. PMID 4032428.
- ^ a b c Hoffman AJ (1987). Synthesis and pharmacological evaluation of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives (Ph.D. thesis). Purdue University. Archived from the original on 29 June 2025. Retrieved 30 June 2025 – via ProQuest.
only partial generalization occurred to norLSD and the N(6)-2-phenethyl derivative at the doses tested. [...] Table 6. 5-HT1 binding affinity of N(6)-alkyl norLSD derivatives. [...] Table 7. 5-HT2 binding affinity of N(6)-alkyl norLSD derivatives. [...] Table 9. Drug discrimination testing results. [...]
- ^ a b Jacob P, Shulgin AT (1994). "Structure-activity relationships of the classic hallucinogens and their analogs". NIDA Research Monograph. 146: 74–91. PMID 8742795.
External links
[edit]
 | This hallucinogen-related article is a stub. You can help Wikipedia by expanding it. |